课题基金 / 基金详情

ANTIGEN PRESENTATION IN HUMAN AUTOIMMUNE DISEASES

ANTIGEN PRESENTATION IN HUMAN AUTOIMMUNE DISEASES
人类自身免疫性疾病中的抗原呈递
批准号:
2892530
负责人:
Kai W Wucherpfennig
金额:
$64.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-30 至 2003-08-31

项目摘要

项目成果

Kai W Wucherpfennig的其他基金

相似基金

相关文献

中文摘要
翻译
不同免疫学研究领域的融合为研究多发性硬化症患者T细胞对抗原的识别提供了机会。多发性硬化是一种中枢神经系统髓鞘炎症性疾病。这些包括阐明TCR识别抗原/MHC的晶体结构;鉴定潜在的生化技术,提供对II类限制性呈现的细胞生物学的见解,并特别强调参与这一过程的蛋白酶。在第一个项目中,我们将利用最新发展的MHC四聚体技术来检测HLA-DR2 MS患者脑脊液和血液中抗原特异性T细胞的频率、激活状态和细胞因子谱,这一点几乎可以肯定被有限稀释技术低估了。将使用TCR四聚体来研究APC在MS病变中呈现髓磷肽的情况,TCR四聚体是由髓鞘特异性T细胞克隆的cDNA产生的,并用于对MS斑块组织进行染色。在第二个项目中,将使用组合多肽文库来检测寡克隆脑脊液T细胞的抗原特异性。这些研究也将在明确CNS感染的受试者身上进行,并将确定MS患者CNS T细胞上表达的TCR在识别组合肽库方面是否与MS患者的CNS T细胞相比在识别病毒或细菌抗原的CNS T细胞上退化。将确定寡克隆T细胞和MBP/DR2四聚体结合T细胞是否反映原始脑脊液群体。项目2将探索CNS小胶质细胞的细胞生物学和生化特性。将研究髓鞘自身抗原MBP和MOG的加工途径以及II类分子和MOG在人小胶质细胞中的运输。通过体外转录/翻译获得的MBP和MOG的制备将作为天然放射性标记抗原的来源,其处理过程将使用生化技术进行监测。这些实验将检测溶酶体蛋白水解酶组织蛋白酶B、D、L或S的作用,它们可能是MBO和MOG在抗原处理中的蛋白水解性转化的候选者。项目1中携带抗原的APC的MOG和MBP原位可视化将被用来检查这些抗原的加工过程。项目1中携带抗原的APC的原位可视化将用于检测项目3中分离的CNS小胶质细胞。用灵敏的技术分析抗原特异性的CD4T细胞将对理解MS的发病机制和任何形式的治疗的免疫监测具有重要意义。
英文摘要
A confluence of different areas of immunological research offers an opportunity for a more synthetic approach to investigate T cell recognition of antigens in patients with MS, an inflammatory disease of the CNS myelin. These include the elucidation of the crystal structure for TCR recognition of antigen/MHC; identification of potential biochemical techniques that provide insights into the cell biology of class II restricted presentation with particular emphasis on the proteases involved in this process. In the first project, we shall utilize the newly developed MHC tetramer technology to determine the frequence, activation state and cytokine profile of antigen specific T cells in the CSF & blood of HLA- DR2 MS patients, which has almost certainly been underestimated by limiting dilution techniques. The presentation of myelin peptides by APC's in MS lesions will be investigated using TCR tetramers generated with cDNAs from myelin specific T cell clones and used to stain MS plaque tissue. In the second project, combinatorial peptide libraries will be used to examine the antigen specificity of oligoclonal CSF T cells. These investigations will also be performed on subjects with defined CNS infections and will determine whether TCRs expressed on CNS T cells in patients with MS are degenerate in their recognition of combinatorial peptide libraries as compared to CNS T cells in patients with MS are degenerate in their recognition of combinatorial peptide libraries as compared to CNS T cells recognizing viral or bacterial antigens. It will be determined whether oligoclonal T cells and MBP/DR2 tetramer binding T cells are reflective of the original CSF population Project 2 will explore the cell-biological and biochemical properties of CNS microglial cells. The processing pathway of the myelin autoantigens MBP and MOG and the trafficking of Class II molecules and MOG in human microglia will be examined. Preparations of MBP and MOG obtained by in vitro transcription/translation will serve as a source of native, radiolabeled antigen, the processing of which will be monitored using biochemical techniques. These experiments will examine the role of lysosomal proteases Cathepsin B, D, L or S, likely candidates for the proteolytic conversion of MBO and MOG in antigen processing. MOG and MBP visualization in situ of antigen-bearing APCs in project 1 will be used to examine the processing of these antigens. The visualization in situ of antigen-bearing APCs in project 1 will be used to examine CNS microglial cells isolated in project 3. Analysis of antigen-specific CD4+ T cells with sensitive techniques will have important implications for understanding the pathogenesis of MS and for immune monitoring by any form of therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
  • 批准号:
    10380449
  • 项目类别:
  • 资助金额:
    $12.57万
  • 财政年份:
    2021
  • 负责人:
    Kai W Wucherpfennig
  • 依托单位:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
  • 批准号:
    10210225
  • 项目类别:
  • 资助金额:
    $35.69万
  • 财政年份:
    2020
  • 负责人:
    Kai W Wucherpfennig
  • 依托单位:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
  • 批准号:
    10029035
  • 项目类别:
  • 资助金额:
    $48.54万
  • 财政年份:
    2020
  • 负责人:
    Kai W Wucherpfennig
  • 依托单位:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
  • 批准号:
    10210221
  • 项目类别:
  • 资助金额:
    $35.92万
  • 财政年份:
    2020
  • 负责人:
    Kai W Wucherpfennig
  • 依托单位:
海外基金